Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test score may flag High-Risk esophageal surgery patients

NCT ID NCT07761975

Knowledge-focused Sponsor: Istanbul Saglik Bilimleri University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This study looks at whether a simple score calculated from routine blood tests—measuring hemoglobin, albumin, lymphocytes, and platelets (the HALP score)—can help predict complications after surgery to remove esophageal cancer. Researchers will track how this score changes before and after surgery in 131 adults and see if it relates to problems like leaks, intensive care needs, or longer hospital stays. The goal is to find out if this easy-to-measure score could serve as a warning sign for patients who may need extra care during recovery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Perioperative HALP score assessment using routine blood tests
What this could lead to
If the HALP score proves useful, it could become a simple, low-cost tool to help doctors identify patients at higher risk of complications after esophageal cancer surgery, potentially improving recovery planning.
What could go wrong
This is a retrospective observational study, so it can only show associations, not cause and effect. The HALP score may not reliably predict outcomes in all patients or settings, and its clinical usefulness remains uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

131 people

The number who actually took part.

Started

Jun 2026

Finished

Jul 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This retrospective cohort study included adult patients who underwent elective esophagectomy with curative intent for histologically confirmed esophageal cancer at a single tertiary referral center between June 2020 and March 2025. Patients with available perioperative laboratory data for calculation of the Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) score before surgery and on postoperative days 1 and 7 were included.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 years or older. * Histologically confirmed esophageal cancer. * Underwent elective esophagectomy with curative intent between June 2020 and March 2025. * Available laboratory data for calculation of the Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) score preoperatively and on postoperative days 1 and 7. * Complete clinical data regarding postoperative outcomes Exclusion Criteria: * Age younger than 18 years. * Benign esophageal disease or surgery performed for indications other than esophageal cancer. * Emergency esophagectomy. * Missing laboratory data required for calculation of the HALP score at any of the predefined time points (preoperative, postoperative day 1, or postoperative day 7). * Incomplete clinical or follow-up data regarding postoperative outcomes.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Esophageal cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

esophageal cancer Postoperative Complications

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Esophagectomy Halp score Perioperative biomarkers Perioperative risk assessment Postoperative complications

Contacts and locations

Locations

  • Basaksehir Cam and Sakura City Hospital

    Istanbul, Istanbul, 34480, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.